{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:59:18Z","timestamp":1790949558047,"version":"4.1.0"},"reference-count":37,"publisher":"Informa UK Limited","issue":"17","funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Roche"},{"name":"Gilead"},{"name":"Takeda"},{"name":"Combat Training Institute"},{"name":"Mundipharma"},{"name":"GlaxoSmithKline"},{"name":"Bayer"},{"name":"Janssen"},{"name":"Karyopharma"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Acerta"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2018,7,31]]},"DOI":"10.2217\/fon-2017-0574","type":"journal-article","created":{"date-parts":[[2018,2,6]],"date-time":"2018-02-06T11:28:48Z","timestamp":1517916528000},"page":"1691-1699","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":11,"title":["Subcutaneous Rituximab with Recombinant Human Hyaluronidase in the Treatment of Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia"],"prefix":"10.1080","volume":"14","author":[{"given":"Samuel Luke","family":"Hill","sequence":"first","affiliation":[{"name":"Medical Oncology, Southampton General Hospital, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davies","sequence":"additional","affiliation":[{"name":"Cancer Research UK Centre, Cancer Sciences Division, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2018,2,6]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_3_2_5_1","unstructured":"World Health Organization . WHO model list of essential medicines (19th Edition) (2015). www.who.int\/medicines\/publications\/essentialmedicines\/en\/."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv303"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw400"},{"key":"e_1_3_2_9_1","unstructured":"European Medicines Agency . Summary of product characteristics \u2013 rituximab. 14\u201316 (2000). www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000165\/WC500025821.pdf."},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.435.435"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.011"},{"issue":"1","key":"e_1_3_2_12_1","first-page":"33","article-title":"Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases","volume":"87","author":"Chow KU","year":"2002","unstructured":"Chow KU , SommerladWD, BoehrerSet al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica87(1), 33\u201343 (2002).","journal-title":"Haematologica"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.877135"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.914033"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S97319"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270012436560"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu524"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.371"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70383-8"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.05.027"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.06.021"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.4.4.427"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0298-x"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAN.0000292572.70387.17"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh176"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.059246"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009337512"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1363993"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080533"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2631"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70005-1"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30078-9"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12662"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00004-1"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.173583"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw685"},{"key":"e_1_3_2_37_1","unstructured":"US FDA . FDA approves rituximab plus hyaluronidase combination for treatment of FL DLBCL and CLL (2017). www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm564235.htm."},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2014.08.1719"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157957"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2017-0574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:39Z","timestamp":1719125079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2017-0574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,6]]},"references-count":37,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2018,7,31]]}},"alternative-id":["10.2217\/fon-2017-0574"],"URL":"https:\/\/doi.org\/10.2217\/fon-2017-0574","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}